A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy.

Trial Profile

A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Vorinostat (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 Jun 2016 Status changed from recruiting to completed.
    • 02 Oct 2012 The dosage of vorinostat changed from 200-600 mg given at different weeks to 400mg given as single dose, paired dose and multiple dose given at different visits, according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top